Farmas USA

Final de sesion jodido para AMRN...muy jodido

CTIX, -3%
ENMD, -3%
IMUC, -2%
MACK -2,5%
SNTA, -2,37%
NWBO, -1%
ARRY, THLD y SBFM planas....

Un puto desastre hoy.....

Por no hablar de las AMRN...

Un saludo

Edito: Queda algo en verdeeeeeeeeeeeeee????????????

....menos esta que no es farma 0.970
+0.205 (+26.81%)
IVAN

GALE

DILUCIÓN

Oppenheimer & Co. Inc. is acting as sole book-running manager for the proposed offering.

The securities described above are being offered by the company pursuant to a "shelf" registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC) on June 12, 2013. A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC.

http://www.streetinsider.com/Stock+Buybacks/Galena+Biopharma+%28GALE%29+to+Offer+Common+Stock/8684473.html?si_client=intbro

GALE, mazazo!!!!!! Oferta de acciones!!!!

Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology treatments to address major unmet medical needs to advance cancer care, announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase common stock are being offered as units. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as sole book-running manager for the proposed offering.

The company intends to use the net proceeds of the offering for the commercialization of its first commercial product, Abstral® (fentanyl) Sublingual Tablets, and its ongoing Phase 3 NeuVax™ (nelipepimut‑S) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial, other clinical trials of its product candidates, and general corporate purposes.

Casi 20 millones , unos 4x del volumen medio. Cosa fina ...
Y eso que la noticia no perjudica ni el adcom ni AMRN pero ya sabemos como es esto.

AMRN

ONVO

Me tiene el culo petado en estos momentos. Posible entrada en 4,80. Dilución recién hecha.

Artículo alcista en SA hoy.

http://seekingalpha.com/article/1690312-organovos-focus-on-long-term-value-creation-going-unnoticed?source=intbrokers_regular

.